Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations
Cancer · 2025
DOI: 10.1002/cncr.35846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Maria R Khouri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Chromosomal Proteins, Non-Histone, Cell Cycle Proteins, Mutation, Myelodysplastic Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
The prognostic impact of cohesin mutations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) is controversial.
Methods
In patients with AML and MDS who underwent next‐generation sequencing at the authors' center during 2017–2023, the authors assessed the landscape of cohesin mutations and the impact of co‐occurring mutations on overall survival (OS) and compared outcomes between patients with cohesin mutations and those with wild‐type (WT) cohesin genes.
Results
The study included 83 patients, 36 with cohesin mutations ( STAG2 , n = 28; SMC1A , n = 7; SMC3 , n = 3; co‐expression of cohesin mutations, n = 2) and 47 with WT cohesin genes. Of the 36 patients with cohesin mutations, 17 (47%) had AML (six de novo and 11 secondary), and 19 (53%) had MDS. Patients who had STAG2 mutations had better median OS than patients who had only SMC1A and SMC3 mutations (26 vs. 10 months; p = .043). SRSF2 mutation was the most frequent co‐occurring mutation ( n = 12; 33%) and was associated with worse median OS than WT SRSF2 (13 vs. 43 months; p = .016). Seven patients (19%) with cohesin mutations underwent hematopoietic transplantation; their median OS was 70 months. Compared with the WT cohesin group, patients who had cohesin mutations were more likely to have adverse‐risk AML (82% vs. 53%). The median OS was similar among patients with adverse‐risk AML in the cohesin‐mutation and WT cohesin groups (10 vs. 14 months, respectively; p = .9).
Conclusions
The current study provides insight into the prognostic impact of cohesin mutations and co‐occurring mutations in patients with myeloid malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Pathology, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA.
ORCID-Profile: Maria R Khouri, Muthalagu Ramanathan
Zitieren
APA
Khouri, M. R., Wang, B., Pearson, L. K., Gillis-Smith, A. J., Suzuki, S., Hutchinson, L. M., Bindal, P., Ramanathan, M., Gerber, J. M., Cerny, J., & Patel, S. A. (2025). Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. https://doi.org/10.1002/cncr.35846
Vancouver
Khouri MR, Wang B, Pearson LK, Gillis-Smith AJ, Suzuki S, Hutchinson LM, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025. doi:10.1002/cncr.35846
BibTeX
@article{Khouri2025,
author = {Khouri, Maria R and Wang, Bofei and Pearson, Laurie K and Gillis-Smith, Andrew J and Suzuki, Sakiko and Hutchinson, Lloyd M and Bindal, Poorva and Ramanathan, Muthalagu and Gerber, Jonathan M and Cerny, Jan and Patel, Shyam A},
title = {Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35846}
}
EUVIMED